Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an immune booster fight rare brain tumors?

NCT ID NCT03173950

NEW Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This phase 2 trial tests whether the immunotherapy drug nivolumab can shrink tumors or slow their growth in adults with rare central nervous system (brain or spine) tumors that have returned after prior treatment. Participants receive nivolumab by IV every 2 to 4 weeks for up to 64 weeks, and researchers monitor tumor response using MRI scans and track survival and quality of life. The goal is to see if stimulating the immune system can help control these hard-to-treat cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (Opdivo), an immunotherapy drug given by IV infusion
What this could lead to
If it works, nivolumab could offer a new treatment option for people with rare central nervous system tumors that have returned, potentially shrinking tumors or delaying their growth.
What could go wrong
This is a phase 2 trial, so results are preliminary. The drug may not work for all tumor types, and it can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL/MALIGNANT MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic meningioma brain cancer Choroid Plexus Neoplasms ependymoma medulloblastoma meningioma Pinealoma spinal cord neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL/MALIGNANT MENINGIOMA CHOROID PLEXUS TUMORS EPENDYMOMA MEDULLOBLASTOMA PINEAL REGION TUMORS

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • UT MD Anderson Cancer Center

    Houston, Texas, 77030-4096, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.